Predicted to enable sodium channel regulator activity; transmembrane transporter binding activity; and voltage-gated sodium channel activity involved in cardiac muscle cell action potential. Predicted to be involved in several processes, including cardiac muscle cell action potential; neuronal action potential; and regulation of sodium ion transport. Predicted to act upstream of or within establishment of localization in cell and sodium ion transmembrane transport. Predicted to be located in intercalated disc. Predicted to be part of voltage-gated sodium channel complex. Predicted to be active in plasma membrane. Human ortholog(s) of this gene implicated in long QT syndrome 10. Orthologous to human SCN4B (sodium voltage-gated channel beta subunit 4); INTERACTS WITH 17beta-estradiol; 2,3,4,7,8-Pentachlorodibenzofuran; 2,3,7,8-tetrachlorodibenzodioxine.
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of SCN4B protein
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of SCN4B protein
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of SCN4B protein
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of SCN4B protein
[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of SCN4B mRNA and [indole-3-carbinol co-treated with Diethylnitrosamine] results in increased expression of SCN4B mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCN4B mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCN4B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCN4B mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCN4B mRNA
[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCN4B mRNA